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Leprechaunism and type A diabetes represent inborn errors of insulin resistance whose
phenotypes suggested causation by mutations in the insulin receptor gene. Cells cultured from
patients with leprechaunism specifically lacked high-affinity insulin binding. Partial but different
degrees of impairment were observed in cells cultured from first-degree relatives. Different
mutations in the insulin receptor's a subunit were proposed in different families (Ark-i, Atl,
Minn, Mount Sinai) based on phenotype, cellular insulin binding, and insulin receptor structure.
Molecular cloning and sequencing of mutant insulin receptor cDNA from family Ark-i
confirmed that the proband inherited a maternal missense and a paternal nonsense mutation in
the a subunit and was a compound heterozygote. The insulin receptor was immunologically
present on the plasma membrane of fibroblasts cultured from patients Ark-I and Atl but was
markedly reduced in cells from patients Minn and Mount Sinai. In cells from patient Minn, but
not from patient Mount Sinai, the decreased number of insulin receptors was associated with
reduced insulin receptor mRNA. In two families with the less severe form of insulin resistance,
type A diabetes, mutations altered post-translational processing ofthe insulin receptor molecule.
At a cellular level, these mutations of the a subunit of the insulin receptor shared defective
binding and impaired stimulation of sugar transport by insulin. In family Atl, however, glucose
uptake was constitutively increased. Thus, genetic variation in the insulin receptor gene causes a
spectrum of inherited insulin-resistant syndromes and altered cellular signaling.
INTRODUCTION
Inborn errors of metabolism represent a group of experiments of nature character-
ized by impaired metabolic flow and caused by single gene mutations. A family study
of any given inborn error could clarify both the pathophysiological and normal
mechanisms ofcomplex metabolic functions in man. This philosophy led to the search
described below for a discontinuous phenotype of inherited severe insulin resistance.
The presumptions are that the candidate gene would be the insulin receptor and that
mutations in this gene would produce insights into the complex mechanisms ofcellular
responses to insulin.
The recent cloning and sequencing of the insulin receptor gene encouraged the
possibility of identifying human phenotypes caused by alterations in the insulin
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receptor [1-3]. Although reduced cellular binding would be a genetic discriminant in
pedigree evaluation, such mutations might also interfere with cellular, signal transduc-
tion mechanisms. Cellular signaling at the plasma membrane is shared by the three
groups of tyrosine protein kinase receptors (Fig. 1). These receptors have in common
an extracellular cysteine-rich, ligand-binding domain, a single transmembrane
domain, and an intracellular tyrosine protein kinase. They are divided into three
classes, based on ligand specificity and structural differences [4].
Class I receptors are composed of a single polypeptide chain containing two
extracellular cysteine-rich regions, which produce one ligand binding pocket. This
class has one intracellular tyrosine kinase domain. The receptor for the epidermal
growth factor (EGF) exemplifies this class [5].
Class II receptors are heterotetramers composed of two a and two,B subunits, linked
by disulfide bonds. The two a subunits are extracellular, each contains one cysteine-
rich region, and binding kinetics differ for different ligands. The insulin receptor, but
not the IGF-I receptor, has complex binding kinetics, suggesting either intramolecular
negative cooperativity or different classes of insulin binding sites in different tissues
[6]. The : subunits span the plasma membrane and carry the kinase domains.
Receptors for insulin and IGF-I typify this class [1,2,7].
Class III receptors are single peptides, like classI, but have two major differences.
First, they have only ten cysteine residues in their extracellular domains, which
presumably produce a pocket for specific ligand binding. Second, their intracellular
cytoplasmic tyrosine kinase is divided by a short (77 or 107 amino acids) sequence,
with the ATP binding site in the N-terminal and the phosphorylated tyrosines in the
C-terminal portion. CSF-l and PDGF receptors exemplify this class [7-9].
Although the exact mechanisms of signal transduction are not fully understood, a
sequence of events is suggested. Ligand binds to the extracellular domain of the
receptor, produces a conformational change, and enhances autophosphorylation.
Activated receptors modulate a variety of cell functions through poorly defined
intermediates, perhaps including specific G proteins [10] (Fig. 1). It should be noted
that different signals are produced in a variety of differentiated cells. Some of these
responses may not require either receptor autophosphorylation or generation of a
kinase reaction [11]. Responses regulated by tyrosine kinase receptors include plasma
membrane functions, such as nutrient and ion transport, and nuclear functions, such as
gene expression and cell division [4,5]. These protein-kinase receptors control cell
growth and have homology to certain oncogenes, such as the EGF receptor for v-erb B
protein product [5]. The insulin receptor shares some homology with the v-ros protein
[I]. This receptor controls both cell growth and a variety of anabolic cell functions
[12]. Cells transfected with insulin receptor cDNAs which alter autophosphorylation
of thed subunit lose insulin-responsive glucose transport [13-16]. By contrast, if the a
subunit of the insulin receptor is truncated, insulin binding is lost, and a constitutive
increase in glucose transport, which is not further stimulated by insulin, occurs in
transfected CHO cells [17].
In man, what phenotype might be associated with specific mutations in the insulin
receptor? Structural alterations in the a subunit of the insulin receptor were proposed
to explain the severe heritable forms of insulin resistance associated with intrauterine
growth restriction, and the syndrome called "leprechaunism" [18,19]. Patients with
leprechaunism are very small for gestational age, have extreme hyperinsulinemia and
altered glucose homeostasis, with fasting hypoglycemia and postprandial hypergly-
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TABLE I
Insulin and IGF-I Binding to Cells Cultured from
Families with Leprechaunism
Specific Binding
Insulin IGF-I
(% ofcontrol)
Controls 100 ± 15 100 ± 25
Ark-I 11 ± 5 98 ± 5
Ark-I mother 63 ± 4 78 ± 10
Ark-I father 15 ± 3 NDA
Atl 11 ± 2 64 ± 4
Atlmother 35 ± 5 132 ± 9
Atl father 34 ± 6 123 ± 4
MountSinai 2 ± 1 11 ± 5
Mount Sinai mother 56 ± 2 NDA
Mount Sinai father 20 ± 2 NDA
Minn 8 ± 6 129 ± 8
Hormone binding was measured in fibroblasts or
lymphoblasts from patients Ark-i, Atl, Minn, Mount
Sinai, and their parents. Data are expressed as percent-
ages of '25I-IGF-I (0.8 ng/ml) and '251-insulin (0.75
ng/ml) binding to matched control cells ± SD ofthree
independent determinations.
NDA, no data available.
cemia [18,19]. Fibroblasts cultured from these patients lack high-affinity insulin
binding, and partial defects in cellular binding are genetic discriminants in genotyping
individuals in these families [20-24]. Some cellular functions are non-responsive to
insulin, but responsiveness varies among different probands and is normal in parents'
cells [22-27]. As shown in Table 1, cells from first-degree relatives express partial
impairment of insulin binding. The binding defect is specific for insulin, since IGF-I
binding to the same cells is within normal range. Thus, an autosomal recessive trait
caused by mutations in the insulin receptor's binding region was proposed as the
mechanism producing leprechaunism [19,22-24]. As evidenced byvariations in insulin
binding defects among probands and first-degree relatives, heterogeneity became part
of this genetic hypothesis. In fact, even within these families a clinical spectrum of
insulin resistance emerged. For instance, the heterozygous father of Ark-I expressed
mild insulin resistance and the Ark-I proband, who is still alive, expresses a unique
phenotype between leprechaunism and type A diabetes [22]. This variation in
phenotypic expression was postulated as due to different mutations in the insulin
receptor gene and their consequent pathophysiology [19,22].
Structure ofthe Insulin Receptor
Several techniques were developed to study the protein structure of the insulin
receptor on plasma membranes of normal and abnormal cultured fibroblasts. Mem-
brane fractions are obtained from cultured cells by differential centrifugation and the
insulin receptor (IR) is then extracted by non-ionic detergents [29]. After this partial
purification, '251-insulin can be cross-linked to the a subunit of the receptor with
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disuccinimidyl suberate (DSS) [22,28,29]. Following separation of membrane pro-
teins by polyacrylamide gel electrophoresis (PAGE), the a subunit of the insulin
receptor was visualized by autoradiography. In non-reducing conditions, the hetero-
tetramer (350 kDa) was visualized. In reducing conditions, the monomeric a subunit
(125-135 kDa) was seen both in control and in leprechaun cells [29]. Higher
concentrations of DSS cross-linked two a subunits, which appeared as a dimeric band
of 250 kDa [29]. In cells cultured from patient Ark-I with leprechaunism, DSS failed
tocross-link a subunits [29]. In cells from patient Ark-1, Kadowaki et al. subsequently
demonstrated a mutation in bp 1507 ofthe insulin receptor cDNA, which resulted in a
conversion Lys460 to Glu [30]. The loss of an e amino group and altered conformation
caused by charge differences probably prevented dimeric cross-linking by DSS [29].
Abnormal cross-linking was not observed in cells derived from other patients with
leprechaunism, again suggesting that different mutations in the insulin receptor
caused these phenotypes ofsevere insulin resistance [29].
The : subunit of fibroblasts' insulin receptors was studied by evaluating insulin-
stimulated autophosphorylation. Insulin binding to its receptor stimulates the incorpo-
ration of 32P, derived from gamma-32P-ATP, into tyrosine residues in the d subunit
[31]. This procedure evaluates not only the size of the : subunit (90-95 kDa) of the
insulin receptor, but also an early response to insulin. The degree of insulin-enhanced
autophosphorylation by cells from patient Ark-I was reduced concomitantly with
insulin binding, suggesting that there was a reduced number ofreceptors on the plasma
membrane, whose autophosphorylation properties were unaffected by the mutation
[29]. Impairment ofinsulin-enhanced phosphorylation has been associated with other
insulin-resistant syndromes. In some patients with type A diabetes and acanthosis
nigricans, insulin binding was not impaired, but defective insulin-stimulated tyrosine
kinase was found [32]. Recently, mutations were identified in the / subunit of the
insulin receptor ofthese patients, mutations which either truncate the,Bsubunit [33] or
alter the ATP binding site of the ,B subunit [34]. In contrast to mutations in the a
subunit, at least one mutation in the ,B subunit of the insulin receptor caused insulin
resistance, which was inherited as an autosomal dominant trait [33]. In some other
patients with type A diabetes, both insulin binding and d subunit autophosphorylation
were impaired [35]. Defined mutations in the /3 subunit of the insulin receptor do not
interfere with insulin binding either in CHO cells or in human fibroblasts [13,33,34],
and further molecular studies are required to define the precise mutation in these
patients.
Immunological methods, such as immunoblotting and radiodisplacement of insulin
receptors, are used to evaluate qualitatively and quantitatively the insulin receptor of
cells derived from patients with severe insulin resistance. Using immunoblotting
techniques, both the a and the ,B subunits were present in fibroblasts' membranes from
patients Ark-I and Atl (Fig. 2). The a subunit band (125 kDa) appeared lighter than
the : subunit band (90 kDa) with this polyclonal antibody. More quantitative
approaches used the radioreceptor displacement assay [36]; by this technique,
heterogeneous levels of insulin receptors were quantified in cell membranes from
different patients with leprechaunism (Table 2). Fibroblasts from patients Minn and
Mount Sinai had the fewest immunoreactive insulin receptors. A partial decrease was
present in cells from patient Ark-i, whereas fibroblasts from patient Atl had a normal
number of receptors. Thus, variation in the number of immunoreactive insulin
receptors further suggested different mutations in the insulin receptor gene. Some may
be point mutations which do not interfere with the formation of a mature receptor,
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FIG. 2. Immunoblots of insulin receptors in the plasma
membrane of fibroblasts cultured from a control, A; patient
Ark-I, B; and Atl, C. Plasma membranes were isolated from
human fibroblasts by differential centrifugation and solubi-
lized with 1 percent Triton X-100 [29]. 200,ug of membrane
proteins were separated on 5-15 percent SDS-PAGE, blotted
to nitrocellulose, recognized by a rabbit polyclonal antibody
directed against the human placental insulin receptor, and
visualized by a second antibody conjugated with peroxidase
[29].
whereas other mutations may impair gene expression, or post-transcriptional or
post-translational processing.
Insulin Receptor Regulation ofMembrane Functions
Insulin regulates amino acid, hexose, and ion transport in target cells [37-43]. In
human fibroblasts, insulin regulates amino acid and sugar transport [41-43].
Biochemical studies in muscle and adipocytes indicated that insulin regulation of
TABLE 2
Immunoreactive Insulin Receptors on Membranes of Fibroblasts
Cultured from Patients with Leprechaunism
Immunoreactive Insulin Receptors % of
(ng/mg of membrane protein) Controls
Controls 9.49 ± 2.82
Ark-1 2.77 29
Atl 9.08 96
Minn 0.75 8
Mount Sinai 0.61 6
Membrane proteins solubilized from human fibroblasts were used
to displace '25I-labeled insulin receptor from insulin receptor-specific
antibodies [46]. Human insulin receptors were purified from placenta
and used as standards (courtesy of Dr. Ira Goldfine).
A B C
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FIG. 3. Schematic representation of insulin regulation of amino acid and sugar transport by two
different mechanisms.
amino acid and sugar transport involved two different mechanisms. Insulin stimulation
ofamino acid transport in muscle [37-39] and in human fibroblasts [43] required new
protein synthesis. By contrast, insulin stimulation of sugar transport was rapid,
independent of protein synthesis [42], and involved the translocation of preformed
intracellular transporters to the plasma membrane [44] (Fig. 3). In muscle and fat
cells, insulin recruited to the plasma membrane a class of glucose transporters which
were uniquely defined immunologically and molecularly (insulin-responsive glucose
transporters [45,46]).
Insulin stimulation of sugar transport was studied in cells from patients with
leprechaunism (Table 3). Insulin failed to stimulate sugar transport in patient Ark-I
cells, produced attenuated responses in fibroblasts from patient Minn, and fully
stimulated glucose uptake by cells from patient Mount Sinai. Glucose uptake by
fibroblasts cultured from patient Atl was unexpectedly different from controls' and
other patients' cells. OMG transport was markedly increased under basal conditions
and non-responsive to insulin. Increased glucose transport was due to a post-
transcriptional enhancement in the number of sugar transporters on fibroblasts'
membrane [23,24]. Basal OMG transport and response to insulin was normal in
fibroblasts cultured from both Atl parents (Table 3). Therefore, partial reduction
in insulin binding to parental fibroblasts did not affect their responsiveness. The
constitutive increase in glucose transport by fibroblasts cultured from patient Atl was
similar to that observed in CHO cells transfected with a truncated insulin receptor
cDNA [17]. In these experiments, 70 percent ofthe a subunit cDNA was deleted, but
all of the d subunit was left intact [17]. CHO cells transfected with this truncated a
subunit receptor exhibited low insulin binding and very high basal glucose uptake
which was insulin-insensitive. These observations suggest that the natural mutation in
patient Atl produced a functionally similar effect on glucose transport to that
artificially introduced in CHO cells, but without a major deletion in the a subunit of
the insulin receptor [29].
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TABLE 3
Effect of Insulin on Initial Rates of 3-0-Methyl-D-Glucose (OMG) Uptake by Human Fibroblasts
3-0-Methyl-D-Glucose
Uptake
(nmol/ml/second)
Cell Density Insulin %
Age Sex (,ug protein/cm2) Basal (1 gg/ml) Stimulation
Control 4 m M 60.2 10.0 ± 0.7 20.1 ± 0.7 +101a
Control I m F 60.1 9.5 ± 0.6 24.4 ± 0.9 +159a
Control 3 m F 32.6 7.6 ± 0.5 19.6 ± 1.6 +159a
Control 33 y F 52.8 8.4 ± 0.3 18.4 ± 0.4 + 1 I9a
Control 25 y M 32.0 11.3 ± 0.4 19.0 ± 0.6 +68a
Control 26y F 46.7 9.7 ± 1.4 20.2 ± 0.2 +108a
Control Range 7.6-11.3 18.4-24.4 +68-159
Ark-i 2.5y F 30.2 10.9 ± 0.9 12.2 ± 1.1 +13
Atl 4m M 50.6 37.7 ± 1.0 39.9 ± 3.2 +6
Atl father 30 y M 40.3 8.3 ± 0.4 21.1 ± 0.8 +156a
Atl mother 28 y F 24.6 9.7 ± 0.6 17.6 ± 0.5 +82a
Minn 2 m F 33.1 11.3 ± 0.6 17.3 ± 0.9 +53'
Mount Sinai 4m F 28.3 9.5 ± 1.2 20.9 ± 0.6 +120a
Confluent monolayers were incubated for one hour in the absence or in the presence of insulin (1
,ug/ml). OMG (1 mM) uptake was then measured for 10 seconds. Each value is the mean ± SD of
triplicates.
0p < 0.01
bp < 0.05 with variance analysis
Insulin stimulation of amino acid transport was normal in cells cultured from
patients Ark-1, Atl, Minn, and Mount Sinai ([22-24], and unpublished results). The
discrepancy between insulin regulation ofamino acid and sugar transport adds genetic
evidence to the biochemical observation that the two membrane functions were
regulated by different signaling pathways. These mutations in the insulin receptor's
binding domain apparently affected only glucose transport stimulation. With specific
monoclonal antibodies it was possible to activate specific responses to insulin.
Monoclonal antibodies that blocked insulin binding to the a subunit of the insulin
receptor stimulated glucose transport without affecting other cellular functions, such
as insulin receptor autophosphorylation [47]. Antibodies directed toward different
epitopes of the a subunit of the insulin receptor enhanced antilipolysis, without
affecting insulin binding [48]. These results suggested that different cellular functions
were sensitive to different conformations of the a subunit both before and after
occupancy by insulin. Different conformational changes may explain why mutations in
the a subunit of the insulin receptor of patients with leprechaunism altered insulin
control ofglucose transport, but left regulation ofamino acid transport unaffected.
An alternative hypothesis may be the presence ofmore than one insulin receptor. A
variant of the human insulin receptor has been described recently in human placenta
[49]. This receptor, which accounts for 6-18 percent of total insulin receptors, binds
insulin and IGF-I with similar affinity. Such a receptor with high affinity but low
insulin-binding capacity, may be spared in some patients with severe insulin resistance,
enabling insulin stimulation ofamino acid transport.
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FIG. 4. Insulin receptor cDNA and mutations which cause heritable severe insulin
resistance.
The Insulin Receptor Gene in Patients with Severe Insulin Resistance
Both the a and the : subunit of the insulin receptor are coded for by a single gene
located on chromosome 19 [1,2,44]. The cDNA for the insulin receptor is approxi-
mately 5.2 kb. Figure 4 schematically shows the correspondence between cDNA
sequence and protein domains in the mature insulin receptor. The a subunit contains
the signal peptide, the cysteine-rich, cross-linking domain, and a poorly defined
ligand-binding domain. The ,B subunit is preceded by a consensus sequence for
Arg-Lys-Arg-Arg which is the site for post-translational proteolytic cleavage. The d
subunit contains a short membrane spanning domain and the tryosine kinase domain.
The latter has an ATP binding site and many tyrosine residues, some of which are
autophosphorylated.
The gene for the insulin receptor is composed of 22 exons and spans more than 120
kb [3]. The 5' pre-transcription region ofthis gene lacks TATA or CAAT sequence but
contains three GC-rich promoters, similar to genes constitutively expressed in eu-
karyotic cells (housekeeping genes [3,50]). Several of the translated exons encode
well-defined functional domains: exon 1, signal peptide; exons 2 and 3, the cysteine-
rich region; exon 15, the transmembranal domain [3]. Exon 11 codes for only 12 amino
acids and is alternatively spliced during RNA processing [51]. This alternativesplicing
explains the differences observed between the two original reported sequences of the
insulin receptor cDNA [1,2].
Portions of this gene are polymorphic [52]. Several restriction fragment length
polymorphisms (RFLPs) have been described. RFLPs arevery frequent in that portion
ofthe gene coding for thejunction between a and A subunits. They are rare in the first
2,000 bp of the coding region [52]. RFLPs have been useful in studying the insulin
receptor gene and its transmission in families with leprechaunism. The insulin receptor
gene of patients Ark-i, Atl, and Minn with leprechaunism presented no private
polymorphisms and therefore no evidence for major deletions or insertions [53]. By
541ELSAS ET AL.
ARK- 1 C C ATL
1 2 3 4 5 6 7 8
+ - + - + - + -
bp
125
100 :
69
56
50
FIG. 5. Amplification and digestion with Mbo 11 of bp
1413-1537 of the insulin receptor gene. Insulin receptor genomic
DNA was amplified by polymerase chain reaction (PCR) and
digested (+) or not (-) with Mbo II. Mbo II cuts the 125 bp
amplified DNA into fragments of 56, 50, and 19 bp, the latter
not seen on this gel. The 100 bp band is nonspecific. Patient
Ark-I (lanes I and 2) has lost a Mbo 11 site on one allele [30],
which results in the appearance of a new 69 bp band (50 ± 19
bp). The 69 bp band is not seen in two controls (lanes 3-6) and in
patient Atl (lanes 7 and 8) (gel courtesy ofClaude T. Ashley).
constructing haplotypes, the transmission of the insulin receptor gene could be
determined. Patient AtI, the product of a consanguineous marriage, was homozygous
for all RFLPs studied and received the same allele from both parents [53]. Atl's
parents differed atonly one offive polymorphic sites. By contrast, patient Ark-i1, whose
parents were unrelated, remained heterozygous for several alleles, and her parents
differed at three out of four RFLPs [52]. Thus RFLP analysis conformed to the
genetic hypotheses developed by pedigree analysis and insulin binding to their cultured
cells [22-24,29].
Reduced insulin binding by cells cultured from some patients also resulted from a
decreased expression of the insulin receptor gene. Cells cultured from patients Ark-i1,
Atl, and Mount Sinai had insulin receptor mRNA comparable to controls ([23,54] and
unpublished results). By contrast, cells from patients Minn and some patients with
type A diabetes had decreased mRNA for the insulin receptor [54,55].
Cells cultured from most patients with leprechaunism express the insulin receptor
gene, but produce a mature protein which is unable to bind insulin. This result
suggested a mutation producing structural alteration in the insulin receptor protein;
this hypothesis was recently confirmed in several families. In family Ark-i, the
proband inherited two noncomplementing mutations in the insulin receptor from her
unrelated parents (Fig. 4) [30]. The father had a mutation at bp 2143 which converted
Gln672 to a STOP codon. It must be noted that the heterozygous father ofpatient Ark-I
expressed a mild form of insulin resistance without leprechaunism [22]. The mother of
542MOLECULAR GENETICS OF SEVERE INSULIN RESISTANCE
~0) C- .
IO 0
.0 0
C 0-
U.
-~~~~~C
~ ~ z
Co
Uo
42.
0~~~~~~
0)~~~~~~~~~~
Cd co C
E <~z
>
CC
C CC.CZ~
CC
2E <
'~~~~~~~~~~~S. 1
0 ~ ~ ~ ~~~~~
0)
Co
c~~~~~~o CZ
0)~~~~~~
CC
CZ z~~~~~~~~~~~~~~~~~~~~~~C
CC~ ~ ~ ~ ~~~~~~~~~~~C
In <
543544 ELSAS ET AL.
Ark-I had a mutation in bp 1507 converting Lys460 into Glu. The proband expressed
only the insulin receptor allele inherited from the mother which lacked Lys460 [30].
This mutation resulted in the loss of a Mbo II restriction site [30]. To determine
whether a similar mutation was present in patient Atl, we amplified bp 1413-1537 of
the insulin receptor gene. The results, shown in Fig. 5, indicated that the insulin
receptor gene ofpatient Atl was different and retained all Mbo II cut sites.
Some patients with type A diabetes also have mutations in their insulin receptor
gene [56,57]. Siblings from Japan whowereproducts ofa consanguineous mating were
homozygous for a mutation in bp 2424 which converted Arg735 into Ser [56]. This
substitution produced a loss of the proteolytic cleavage site between the a and the ,3
subunit. It generated a defective, unprocessed polypeptide chain. In another consan-
guineous family, the mutation at bp 1363 of the insulin receptor cDNA converted
Phe382 into Val. This substitution caused impaired post-translational receptor process-
ing and markedly reduced the number of insulin receptors on the plasma membrane
[57].
Heterogeneity ofDefects in the Insulin Receptor
Table 4 summarizes the results obtained in different patients with a spectrum of
familial severe insulin resistance. At least eight different mutations in the insulin
receptor gene are likely, based on binding, structure, function, and sequence data from
these families. Abnormalities in the insulin receptor arise from decreased gene
expression, from altered post-translational processing, and from point mutations which
produce proteins with impaired insulin binding. With further application of these
molecular techniques, a much larger number of mutations and pathophysiological
sequelae are expected.
The studies described above indicate that the insulin receptor is altered in patients
with a wide variety ofclinically expressed insulin resistance. Different mutations in the
a subunit ofthe insulin receptor cause different phenotypes. Mild insulin resistance is
observed in heterozygotes with one mutant allele; however, the heterozygotes do not
have growth restriction or other somatic signs of leprechaunism. Mutations in the
insulin receptor gene may contribute to the development of common forms of insulin
resistance, non-insulin-dependent diabetes mellitus (NIDDM II). In some families,
RFLPs in the insulin receptor gene co-segregate with maturity onset diabetes of the
young [58]. Furthermore, some RFLPs in the insulin receptor gene are in linkage
disequilibrium with a Chinese population expressing NIDDM II [59]. NIDDM II is
not a single gene disorder and will not be explained by genetic variations in the insulin
receptor gene alone; however, such genetic variation may produce susceptibility to
other environmental and genetic factors. Further molecular and physiological studies
of families with inborn errors of the insulin receptor will clarify both the normal
mechanisms by which insulin signals cellular responses and shed light on common
disorders characterized by insulin resistance.
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